Rhumbline Advisers Sells 3,382 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Rhumbline Advisers decreased its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 9.0% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 34,186 shares of the biotechnology company’s stock after selling 3,382 shares during the period. Rhumbline Advisers owned approximately 0.13% of Arcturus Therapeutics worth $832,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. ARK Investment Management LLC grew its stake in shares of Arcturus Therapeutics by 16.3% during the second quarter. ARK Investment Management LLC now owns 1,964,964 shares of the biotechnology company’s stock worth $47,847,000 after acquiring an additional 275,315 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Arcturus Therapeutics by 3.1% during the second quarter. Bank of New York Mellon Corp now owns 119,181 shares of the biotechnology company’s stock worth $2,902,000 after acquiring an additional 3,578 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in shares of Arcturus Therapeutics by 8.5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 34,660 shares of the biotechnology company’s stock worth $844,000 after acquiring an additional 2,730 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its stake in shares of Arcturus Therapeutics by 22.4% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,563,065 shares of the biotechnology company’s stock worth $38,061,000 after acquiring an additional 286,546 shares during the last quarter. Finally, Harbor Capital Advisors Inc. grew its stake in shares of Arcturus Therapeutics by 311.5% during the second quarter. Harbor Capital Advisors Inc. now owns 65,667 shares of the biotechnology company’s stock worth $1,599,000 after acquiring an additional 49,709 shares during the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Wall Street Analyst Weigh In

ARCT has been the topic of a number of research analyst reports. HC Wainwright boosted their price target on Arcturus Therapeutics from $60.00 to $63.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Leerink Partners initiated coverage on Arcturus Therapeutics in a research report on Monday, August 12th. They issued an “outperform” rating and a $70.00 target price on the stock. Leerink Partnrs upgraded Arcturus Therapeutics to a “strong-buy” rating in a research report on Monday, August 12th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $71.40.

Arcturus Therapeutics Trading Up 2.6 %

Shares of NASDAQ:ARCT opened at $21.15 on Tuesday. Arcturus Therapeutics Holdings Inc. has a 12-month low of $17.52 and a 12-month high of $45.00. The company has a market capitalization of $569.61 million, a PE ratio of -5.41 and a beta of 2.60. The business has a 50 day moving average of $21.11 and a two-hundred day moving average of $26.95.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.85) by $1.21. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. The company had revenue of $49.86 million during the quarter, compared to the consensus estimate of $21.00 million. During the same period in the previous year, the company posted ($1.98) earnings per share. Equities research analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.6 earnings per share for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.